Claim OwnershipGlobal HIV Vaccine Enterprise AIDS Vaccine 2012 Conference
Subscribed: 2Played: 27
Subscribe
© Copyright 2012, Global HIV Vaccine Enterprise
Description
Select sessions at the Global HIV Vaccine Enterprise AIDS Vaccine 2012 Conference
121 Episodes
Reverse
Closing Session
Bill Snow Global HIV Vaccine Enterprise, New York, NY United States of America Galit Alter Conference Chair, Boston, MA United States of America Dan Barouch Conference Chair, Boston, MA United States of America José Gatell 2013 Conference Chair, Barcelona, Spain Bonaventura Clotet 2013 Conference Chair, Barcelona, Spain
Rapporteurs: Animal Models: What Can Our Furry Friends Teach Us? by Nichole Klatt National Institute of Health, Bethesda, MD United States of America
Rapporteurs: Vaccimunology: Advances in Our Understanding of Immune Correlates by Julie Boucau The Ragon Institute of MGH, MIT and Harvard, Boston, MA United States of America
Rapporteurs: People: Where Do We Stand with Moving Towards Efficacy Trials? by Magdalena Sobieszczyk Columbia University, New York, NY United States of America
Rapporteurs: The Target: How Do We Hit the Virus Where it Hurts? by Morgane Rolland MHRP, HJF, Bethesda, MD United States of America
Plenary Session 03: New Concepts in Immune Induction: Experimental HIV-vaccines induce immunological memory in murine and human NK cells by Silke Paust Harvard Medical School, Boston, MA United States of America
Plenary Session 03: New Concepts in Immune Induction: Follicular T helper cells in vaccination and lentivirus pathogenesis by Richard A. Koup Vaccine Research Center, Bethesda, MD United States of America
Symposia 08: Therapeutic Vaccination and Strategies for the Cure: Assembling the Tools to Clear HIV Infection: Contributions from Virology and Immunology by David Margolis University of North Carolina at Chapel Hill, Chapel Hill, NC United States of America
Symposia 08: Therapeutic Vaccination and Strategies for the Cure: Persistence of Latently Infected CD4+ T cells During HAART: Keeping Memory, Keeping HIV by Nicolas Chomont VGTI FL, Port Saint Lucie, FL United States of America
Symposia 08: Therapeutic Vaccination and Strategies for the Cure: Barriers to HIV-1 Eradication by Robert Siliciano Johns Hopkins University School of Medicine, Baltimore, MD United States of America
Symposia 08: Therapeutic Vaccination and Strategies for the Cure: Therapeutic Vaccines in Strategies for Functional Cure of HIV by Brigitte Autran JINSERM U543 - Université Paris VI Pierre et Marie Curie, ORVACS, Paris, France
Symposia 08: Therapeutic Vaccination and Strategies for the Cure: Therapeutic Approaches to Curing HIV Infection by Steven Deeks University of California, San Francisco, San Francisco, CA United States of America
Symposia 07: Priming Effective B Cell Responses: CD40L Adjuvant for DNA/MVA Vaccine: Enhanced Protection from Acquisition of Neutralization Sensitive & Neutralization Resistant Mucosal SIV Infections by Suefen Kwa Emory University, Microbiology and Immunology, Atlanta, GA United States of America
Symposia 07: Priming Effective B Cell Responses: Genetic and Structural Basis for Development of High Affinity Antibodies by James Crowe Vanderbilt University, Nashville, TN United States of America
Symposia 07: Priming Effective B Cell Responses: Evolution of Broadly Cross-neutralizing Antibodies During HIV-1 Infection by Penelope L. Moore National Institute for Communicable Diseases, Johannesburg, South Africa
Symposia 07: Priming Effective B Cell Responses: T Follicular Helper Cells in HIV Infection by Hendrik Streeck Ragon Institute of MGH, MIT and Harvard, Boston, MA United States of America
Symposia 07: Priming Effective B Cell Responses: The Unique T Cell Receptor Expressed by Each Naive Helper T Cell Instructs Effector Cell Fate by Marc K. Jenkins University of Minnesota, Minneapolis, MN United States of America
Symposia 06: Preclinical Studies and Vaccine Platforms: E-DNA IM or ID Delivery Prime Enhances Antibody and T Cell Responses Following Recombinant gp120 Env Boost by David B. Weiner University of Pennsylvania,Pathology and Laboratory Medicine, Philadelphia, PA United States of America
Symposia 06: Preclinical Studies and Vaccine Platforms: Passive Immunization for HIV Prevention by Francine McCutchan Bill & Melinda Gates Foundation, Seattle, WA United States of America
Symposia 06: Preclinical Studies and Vaccine Platforms: Pre-clinical Studies and Vaccine Platforms Using Chimp Adenovirus Vectors by Tomá? Hanke University of Oxford, The Jenner Institute, Oxford, United Kingdom (Great Britain)
Comments
Download from Google Play
Download from App Store
United States